GSK GlaxoSmithKline PLC
Company Analysis
Latest News
GSK signs $1.3 billion HUTCHMED deal, targeting KRAS-driven cancers
GSK secured an exclusive worldwide licensing agreement with HUTCHMED for the cancer therapy HMPL-A830. HUTCHMED will retain development and commercialization...
GSK’s Jemperli wins FDA priority review, potentially replacing rectal cancer surgery
The U.S. Food and Drug Administration (FDA) accepted GlaxoSmithKline’s application for Jemperli (dostarlimab) under Priority Review. This application seeks...
Dodge & Cox Reduces Stake in GSK by 17.8%
In a quarterly filing with the SEC, investment manager Dodge & Cox disclosed a reduction in its position in GSK PLC. The report, which covers the period ending...
GSK Secures Rights to Chugai’s Dengue Antibody, Targeting Global Health Threat
GSK plc secured an exclusive global license from Chugai Pharmaceutical Co Ltd for the anti-dengue antibody AID351. The agreement grants GSK full rights for the...
GSK Pharma Profit Climbs 15.7%, Driven by Vaccine and Medicine Sales
GlaxoSmithKline Pharmaceuticals reported a 15.7% year-over-year increase in consolidated net profit for the quarter ended June 30, 2026. Net profit reached...
GSK Targets $2.5B in Savings, Doubling Drug Trials Before Patent Expiry
GSK announced a three-year restructuring plan to save £1.9 billion ($2.5 billion) annually by 2029. The initiative simplifies the organization to reallocate...
GlaxoSmithKline PLC Q2 2026 Earnings Preview: What Analysts Expect on July 28, 2026
GlaxoSmithKline PLC is projected to report Q2 2026 revenue of $10.79 billion and earnings per share of $1.27, with the stock currently trading at $51.39...
GSK cancer drug Ris-Rez hits survival goal in pivotal Phase 3 trial
GSK announced Friday that its licensed cancer therapy, risvutatug rezetecan (Ris-Rez), met its primary endpoint of overall survival. The pivotal Phase 3 trial...
GSK completes £2B buyback, clears path for Blenrep US growth
GSK has completed its £2 billion share buyback program to reduce outstanding shares and enhance shareholder returns. The company is also pursuing a cash...
GSK secures Canada approval for Exdensur, first twice-yearly asthma biologic
Health Canada approved GSK’s Exdensur (depemokimab) for the treatment of severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. This...
GSK Wins FDA Approval for Utebzi, First Oral Alternative to IV Antibiotics
GSK and Spero Therapeutics received FDA approval for Utebzi (tebipenem pivoxil) to treat complicated urinary tract infections (cUTIs) and pyelonephritis. This...
GSK Buys Nuvalent for $10.6 Billion, Its Largest Deal of 2026
GSK agreed to acquire Nuvalent for approximately $10.6 billion. The purchase price is $124 per share. This represents a 40% premium to the last closing price....
GlaxoSmithKline PLC Q1 2026 Earnings Preview: What Analysts Expect on April 29, 2026
Consensus revenue for Q1 2026 is projected at $10.19 billion alongside an EPS of $1.19, with the current stock price of $54.60 trading near the average analyst...